MDR 2017 Made Simple – Chapter III: Meet India’s Regulatory Gatekeepers (CLA, SLA & Notified Bodies)

MDR 2017 Made Simple: Chapter III – Authorities & Bodies (Part 3 of 12)

By Ankur K. Khare – Biomedical Engineer | AI Ethics & Medical Innovation

Welcome to Part 3 of our 12-part MDR 2017 series! Having mastered definitions and classification, it’s time to meet India’s regulatory gatekeepers. Chapter III maps who does what—ensuring you approach the right authority at every step.

Why Understanding Authorities Matters

Misrouting applications wastes time, money, and can even invalidate your submissions. Knowing which body has jurisdiction:

·         Speeds up approvals

·         Prevents rejections due to “wrong office”

·         Clarifies appeal and grievance processes

The Three Pillars of Regulation

1. Central Licensing Authority (CLA)

·         Who: The Drugs Controller General of India (DCGI) at CDSCO

·         Jurisdiction:

o    Import and manufacture of Class C & D devices

o    Clinical investigation permissions for high-risk devices

o    Conformity assessment of notified bodies

·         Key Roles:

o    Granting Form MD-17 manufacturing licenses for Class C/D

o    Approving Form MD-23 clinical investigation applications

o    Coordinating nationwide regulatory policy

2. State Licensing Authority (SLA)

·         Who: State Drugs Controllers in each state

·         Jurisdiction:

o    Manufacture of Class A & B devices

o    Sale and distribution of all classes within the state

·         Key Roles:

o    Issuing Form MD-5 (Class A/B) manufacturing licenses

o    Conducting local inspections of manufacturing sites

o    Enforcing post-market surveillance actions at state level

3. Notified Bodies

·         Who: Third-party organizations accredited by the National Accreditation Board for Certification Bodies (NABCB)

·         Jurisdiction:

o    Conformity assessment and quality audits for applicable devices

o    Technical review of manufacturer QMS and design dossiers

·         Key Roles:

o    Issuing conformity assessment certificates

o    Performing unannounced audits and technical evaluations

o    Liaising with CLA for recommendations

How They Work Together: The Regulatory Workflow

1.       Product Development & QMS Setup

o    Choose appropriate QMS standard (ISO 13485)

o    Engage notified body for initial gap analysis

2.      Clinical Investigation Approval

o    For Class C/D or novel devices: Submit MD-22 to CLA

o    Acquire ethics-committee clearance

3.      Manufacturing License Application

o    Class A/B: Apply MD-3 → MD-5 with SLA

o    Class C/D: Apply MD-16 → MD-17 with CLA

4.      Import License (if applicable)

o    Authorized Indian agent applies MD-14 → MD-15 with CLA

5.       Post-Market Surveillance & Reporting

o    Both SLA and CLA share adverse-event data

o    Notified bodies audit QMS and submit findings

6.      Inspections & Enforcement

o    SLA inspects Class A/B facilities

o    CLA inspects Class C/D and oversees notified bodies

Real-World Application: Case Studies

Case Study 1: Class A Hearing Aid Manufacturer

·         Action: Manufacturer submitted Form MD-3 to SLA

·         Result: License granted in 45 days after SLA inspection

·         Tip: Proactively include QMS manual to avoid queries

Case Study 2: Class D Pacemaker Importer

·         Action: Foreign manufacturer’s agent applied MD-14 to CLA

·         Challenge: Required free-sale certificate + ISO 13485 audit report

·         Result: Import license in 6 months; leveraged notified body audit to accelerate review

Case Study 3: AI Radiology Software Clinical Trial

·         Action: Developer applied MD-22 for clinical investigation to CLA

·         Complexity: Ethics-committee approval, GCP compliance, notified body validation

·         Outcome: Trial approval in 90 days; software routed through CLA due to Class C classification

Common Pitfalls & How to Avoid Them

·         Misidentifying Authority: Confirm device class before choosing SLA vs CLA

·         Incomplete Applications: Attach all annexures (QMS certificate, device master file, free-sale certificate)

·         Ignoring Notified Body: Early engagement avoids last-minute conformity issues

·         Overlooking State Variations: Some states require additional local permits for facility modifications

Exam-Ready Cheat Sheet

·         CLA (DCGI): Class C/D manufacture, import, clinical trials

·         SLA (State): Class A/B manufacture, sale/distribution statewide

·         Notified Body: Third-party QMS audits, conformity certificates

·         Key Forms:

o    MD-3 & MD-5: Class A/B manufacture

o    MD-16 & MD-17: Class C/D manufacture

o    MD-14 & MD-15: Import license

o    MD-22 & MD-23: Clinical investigation

Looking Ahead: What’s Next?

In Part 4, we’ll navigate Chapter IV: Manufacturing—covering license applications, QMS requirements, and audit readiness so your facility can produce compliant devices from Day 1.

Join the Conversation

Question: Which authority did you find most challenging to engage with, and why?
Poll: What’s your biggest concern?

·         Clinical trial approvals

·         QMS certification delays

·         Import license hurdles

·         State-level inspections

Share your experiences and let’s learn together!

Key Takeaways

·         Right authority, right class: Saves months of delays

·         Early notified-body engagement: Prevents conformity surprises

·         Complete documentation: Critical for smooth approval

·         CLA vs SLA clarity: Essential for strategic planning

This is Part 3 of our 12-part MDR 2017 series. Next: Chapter IV – Manufacturing Essentials. Stay tuned!